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Abstract: Reduction in testosterone levels in men during aging is associated with cognitive decline and risk of dementia. 
Animal studies have shown benefits for testosterone supplementation in improving cognition and reducing Alzheimer’s 
disease pathology. In a randomized, placebo-controlled, crossover study of men with subjective memory complaint and 
low testosterone levels, we investigated whether testosterone treatment significantly improved performance on various 
measures of cognitive functioning. Forty-four men were administered a battery of neuropsychological tests to establish the 
baseline prior to being randomly divided into two groups. The first group (Group A) received 24 weeks of testosterone 
treatment (T treatment) followed by 4 weeks washout, and then 24 weeks of placebo (P); the second group (Group B) 
received the same treatments, in reverse order (Placebo, washout, and then T treatment). In group A (TèP), compared to 
baseline, there was a modest (1 point) but significant improvement in general cognitive functioning as measured by the 
Mini Mental State Examination (MMSE) following testosterone treatment. This improvement from baseline was sustained 
following the washout period and crossover to placebo treatment. Similar Mini Mental State Examination (MMSE) scores 
were observed when comparing testosterone treatment with placebo. In group B (PèT) a significant increase was observed 
from baseline following testosterone treatment and a trend towards an increase when compared to placebo treatment. 
Improvements in baseline depression scores (assessed by Geriatric Depression Scale) were observed following 
testosterone/placebo treatment in both groups, and no difference was observed when comparing testosterone with placebo 
treatment. Our findings indicate a modest improvement on global cognition with testosterone treatment. Larger clinical 
trials with a longer follow- up and with the inclusion of blood and brain imaging markers are now needed to conclusively 
determine the significance of testosterone treatment. 
Keywords: Testosterone, Androgen, cognition, ageing, memory, dementia, depression, Apolipoprotein E, Alzheimer’s disease. 
1. INTRODUCTION 
 Aging is associated with a gradual decline in sex 
hormone levels in men, together with a deterioration in 
general health, mood and cognitive abilities. In 
epidemiological studies of healthy older men, higher 
testosterone concentrations have been associated with better 
global cognition, executive functions, and verbal memory  
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[1]. Most recently, testosterone levels have been associated 
with an increase in the brain amyloid load, a major 
Alzheimer’s disease (AD) pathological hallmark, in men at 
risk of AD [2]. 
 The potential benefits of testosterone replacement 
therapy for the safety and physiological assessment has been 
demonstrated in men with low testosterone levels and who 
have subjective memory complaints at risk of cognitive 
decline [3]. Even elderly men who are above 65 years old 
with late onset hypogonadism benefit as much as the 
younger men in terms of safety profile and increasing 
testosterone levels [4]. With respect to cognition, although 
cell culture and animal studies have provided support for 
testosterone in having potential therapeutic benefits in AD 
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[5]. there have been relatively few studies that have trialed 
testosterone supplementation in men with AD or mild 
cognitive impairments (MCI) and none have evaluated 
testosterone treatment in individuals that are pre-
symptomatic but at a greater risk of cognitive decline. These 
studies have shown mixed outcomes with improvements in 
certain cognitive domains [6], to no improvement [7, 8]. A 
number of factors may account for the discrepancies in the 
outcomes of these trials, including differences in type, mode 
and dosage of treatment. Furthermore, modifying roles for 
genetic factors such as the presence of the AD risk factor, 
apolipoprotein E (APOE ε4) allele, may also influence 
outcomes of trials and the benefits of testosterone on 
cognition or AD like pathology [9]. In addition, testosterone 
supplementation as potential prevention and/or therapeutics 
prevention of AD should start at the earliest phase of the 
disease when primary prevention may provide maximal 
benefit. In the current study, the efficacy of testosterone 
treatment on cognitive function and depression was assessed 
during a six-month, double blind, cross-over treatment trial 
in older men with subjective memory complaints and low 
testosterone levels. 
2. MATERIALS AND METHODS 
2.1. Participants 
 This study was undertaken at the Siloam Hospital in 
Lippo Karawaci, Tangerang, Indonesia. Ethics approval was 
obtained from the Independent Human Ethics Committee, 
Faculty of Medicine, University of Indonesia as well as from 
Edith Cowan University, Western Australia. Informed 
consent was obtained from all participants prior to the study. 
Participants were recruited from all areas surrounding 
Jakarta and Tangerang, Indonesia. The eligibility criteria 
included: 1) Males aged ≥50 yrs old; 2) Presenting with 
subjective memory complaints; 3) Testosterone levels of 
300- 600 ng/dL (~10.4-20.8 nmol/L); 4) Normal prostate-
specific antigen (PSA) levels; 5) Normal blood pressure of 
120/80 mmHg to 90/60 mmHg; 6) No diagnosis of diabetes 
mellitus; 7) Normal liver and kidney enzyme function; 8) No 
previous history of severe head injury and stroke ; 9) No 
significant history of alcohol abuse ; 10) Normal cognitive 
function, established using a score ≥24 on the Mini Mental 
State Examination (MMSE); and 11) ≥6 years of education. 
A clinical panel consisting of a neurologist and a 
neuropsychologist reviewed each volunteer’s cognitive and 
pathology blood results prior to recruitment into the study. 
 Fig. (1) depicts the participant recruitment and 
randomization process and outlines number of participants 
recruited from the initial screen and drop-outs during this 
double blind, randomized study. A total of 44 men were 
assigned to one of the two parallel, crossover groups, starting 
with placebo (n=22) or testosterone (n=22) treatment and 
transferred to testosterone and placebo after a 4 week wash-
out period. Assignment was random using stratification for 
memory performance at baseline. Each participant had a total 
of 11 clinic visits within the 52-week study period. 
Intervention included applying a testosterone cream, namely 
50 mg of AndroForte® 5% manufactured by Lawley 
Pharmaceuticals, Perth, Australia, applied daily to the 
scrotum via transdermal route for a period of 24 weeks. This 
cream contains dl-α- tocopherol acetate (vitamin E) and 
almond oil formulated to protect testosterone from oxidation. 
It also contains cetomacrogol 1000, cetostearyl alcohol, 
butylated hydroxytoluene, anhydrous citric acid, 
triethanolamine, carbomer 940, B & J Phenonip® and 
purified water. The placebo included dl-alpha tocopherol 
acetate (vitamin E) only [without the active ingredient: 
testosterone] and was applied in a similar manner to the 
testosterone cream. Dose and site of application were 
evaluated in a separate small pilot study as presented in 
supplementary information. 
2.2. Clinical and Neuropsychological Measures 
 Neuropsychological measurements were performed at 
four different time points: week 0 (baseline), week 24 (1st 
treatment period), week 28 (washout period) and week 52 
(2nd treatment or cross-over period), while blood biomarker 
measurements and apolipoprotein (APOE) genotyping were 
performed as described previously [3]. Global cognitive 
function was assessed using the Mini Mental State 
Examination (MMSE) [10]. Verbal memory was assessed 
using Rey Auditory Verbal Learning Test (RAVLT) [11]. 
Comparable, parallel Indonesian versions of the RAVLT 
were administered at each time point to limit the practice and 
learning effects. A standardized Indonesian translation of 
Geriatric Depression Scale (GDS-30) with a cut off score of 
≥11 was used to measure depressive symptoms [12]. 
Physicians, participants, and investigators were blind to the 
treatment conditions. 
2.3. Statistical Analysis 
 Statistical analysis was performed using the Statistical 
Package for Social Sciences (SPSS version 21, SPSS Inc, 
Chicago, IL). The Kolmogorov-Smirnov and Levene’s tests 
for the MMSE, RAVLT, and GDS indicated normally 
distributed data. To analyse each arm of the study 
individually (testosterone to placebo “TP” and placebo to 
testosterone “PT”) and overall, a mixed model ANOVA 
analysis was used, consisted of fixed effects for treatment (to 
compare testosterone and placebo treatments), treatment 
period (testosterone or placebo), and sequence (testosterone 
treatment first or placebo treatment first). Carry-over effects 
were investigated by looking for differences between 
baseline readings and readings at week 28 after the washout 
period (weeks 24-28), was considered as the baseline reading 
for the second treatment period. To analyse the results of 
each treatment arms independently, one-way repeated 
measures ANOVA was performed. 
3. RESULTS 
 A total of 44 elderly men (32 APOE ε4 non carriers, 72% 
and 12 APOE ε4 carriers) were randomized. Participants in 
both TP & PT groups were comparable on age and 
education (Age : TP 59.2 + 7.2, PT 62.9 + 8.2 ; 
Education: T P 13.9 + 2.8, PT 13.7 + 3.3). There were 
no significant differences in age or education between the 
APOE ε4 carriers and non-APOE ε4 carriers. 
 Testosterone supplementation significantly increased the 
serum levels of T and its metabolite DHT and reduced the 
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LH levels, when compared to baseline, placebo 
administration or the washout period prior to crossover 
treatment. Estradiol levels were similar following all 
treatment periods (Tables 1 and 2). The results confirm that 
the treatment regime was effective at increasing serum 
testosterone and lowering LH levels. 
3.1. Effects of Testosterone on Measures of Cognitive 
Functioning and Depression 
 Compared to baseline MMSE scores, participants in the 
testosterone then placebo (TP) the treatment arm (Group 
A) showed a modest but significant improvement with 
testosterone supplementation (Table 1). The MMSE scores 
of participants from the TP arm remained at 
approximately the same level for 52 weeks despite the fact 
that testosterone treatment had been stopped at week 24 and 
replaced with placebo at week 28 following the washout 
period. In the PT arm (started with placebo and transferred 
to testosterone after the washout period, Group B) the 
MMSE scores were only increased when they started the 
testosterone application (Table 2). In both treatment arms, no 
significant changes in MMSE scores were observed from 
baseline following placebo treatment. In both groups, MMSE 
scores were similar when comparing testosterone treatment 
with placebo treatment. Also, no significant differences were 
observed in verbal memory across treatment groups as 
measured by immediate and delayed recall on the RAVLT 
(Tables 1 and 2). 
 Depression scores significantly decreased following 
testosterone treatment and the observed improvement 
maintained during the washout and following crossover to 
the administration of placebo compared to baseline in the 
TP treatment (Group A) (Table 1). Interestingly, the 
placebo group showed a trend towards improvement in their 
follow up depression scores compared to the baseline in the 
PT treatment (Group B) (Table 2). When compared to 
placebo, testosterone treatment significantly decreased 
depression scores in the TP treatment, but not the PT 
treatment (Tables 1 and 2). 
4. DISCUSSION 
 Our findings showed that significant improvements in 
baseline MMSE scores occurred after testosterone treatment 
in both arms of the study compared to baseline, consistent 
with previous studies assessing testosterone in AD and MCI 
subjects. In addition, when testosterone was administered 
first, we saw an improvement in MMSE score at the end of 
the washout and placebo phases. This finding suggests that 
there may be carry-over effect of testosterone treatment. 
These potentially lasting, beneficial effects of testosterone on 
global cognition are in line with previous studies that 
indicated changes in cognitive capacity following hormonal 
manipulation do not return to baseline levels but are 
preserved or continue to change in the same direction after 
cessation of hormone treatment [7, 13]. This finding may 
partially be a by-product of baseline hormonal state because 
it has been indicated that baseline hormonal state may affect 
ones response with carry-over effects [14]. A comparison 
between placebo and testosterone treatment in group B 
(commenced with placebo treatment), revealed no significant 
differences (although a trend towards an increase was noted, 
p=0.087). It is not clear why no differences were observed in 
comparing placebo and testosterone. One potential 
contributing factor maybe the similar ingredient that made 
up the base of the cream. Both creams contained low doses 
of dl-α-tocopherol acetate (Vitamin E) and almond oil to 
allow greater systemic absorption of testosterone. Vitamin E 
has shown to alter cognition in AD and MCI patients at 
~2000 IU/day when consumed orally from 6 months to 4 
years [15, 16]. In our study the cream contained less than 5% 
of the dose of Vitamin E needed for clinical efficacy 
(~111IU/day) and was administered topically, thus it is 
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unlikely that enough Vitamin E was systemically absorbed to 
have cognitive enhancing effects. 
 There are, however, conflicting findings on the effects of 
testosterone on global cognition with studies showing no 
evidence of cognitive enhancing properties with testosterone. 
A randomized double blind placebo controlled study by 
Haren et al., 2005, showed no increase in MMSE scores in 
76 men following 12 months of oral testosterone 
undecanoate or placebo, after taking into the account of the 
baseline hormone and MMSE levels [17]. Another study by 
Kenny et al., 2004 also showed no significant changes in 
global cognitive performance with 12 weeks of 
intramuscular testosterone treatment in older men with early 
cognitive decline and low testosterone levels [18]. 
 Despite relatively modest improvements in baseline 
global cognition with testosterone, our study showed no 
beneficial effects on episodic verbal memory. This finding is 
in accordance with those from another study that did not 
show a consistent improvement across all cognitive domains 
in relation to higher levels of testosterone [19]. While some 
studies have found an association between testosterone and 
verbal memory [20, 21], other studies have not reported 
similar results [22, 23]. Moreover, the improvement on 
verbal memory was found to last only for a short term, as 
shown by Cherrier et al., 2015 that this improvement was 
observed at 3 months and was not sustained at 6 months of 
treatment [20]. It has been suggested that inconsistencies in 
these studies could be explained by the concept of changes in 
the optimal testosterone range and the possibility of a 
curvilinear association between testosterone and cognitive 
performance [19, 21]. For example, Cherrier et al. (2007) 
reported that men with moderate increases in serum 
testosterone and its metabolites showed significant 
improvements in verbal and spatial memory, but that these 
effects were not observed in men with larger or negligible to 
low increases in testosterone concentration. In addition, men 
who had higher levels of both testosterone and E2 
subsequent to testosterone treatment showed better 
performance on tests of verbal memory compared to pre-
treatment scores and compared to placebo treatment [21]. 
The E2 levels reached in our study (following transdermal 
testosterone administration) may not have been sufficient to 
improve memory. The peak serum levels of E2 in our study 
Table 1. Cognitive scores and serum testosterone, DHT and estradiol for men that were administered Testosterone then Placebo 
(Group A, n=22, Mean±SD). 
 
 Baseline (Week 0) Testosterone (Week 24) Wash Out Placebo (Week 52) 
MMSE1 27.3±1.7 28.3±1.5* 28.0±1.2* 28.2±1.3* 
RAVLT2     
Immediate Recall3 44.3±6.9 46.9±7.8 47.9±7.9 47.0±10.1 
Delayed Recall 8.4±2.2 8.9±1.9 9.5±2.5 9.6±2.6 
GDS4 7.1±5.5 4.5±3.3*# 3.5±3.1* 3.2±2.8* 
Testosterone (nmol/L) 16.5±4.4 26.7±12.1*# 17.3±4.4 15.3±4.1 
DHT (nmol/L) 1.84±0.9 9.1±4.9*# 1.8±1.7 1.7±0.8 
Estradiol (pmol/L) 81.2±22.7 85.6±33.8 83.1±7.9 92.4±18.6 
LH (U/L) 4.2±2.8 2.1±1.2*# 4.2±2.4 4.8±3.3 
1Mini Mental State Examination; 2Rey Auditory Verbal Learning Test; 3RAVLT Learning Trial 1-5 total score; 4Geriatric Depression Scale. *p<0.05, values significantly different 
compared to baseline; #p<0.05, values significantly different compared to placebo. 
 
Table 2. Cognitive scores and serum testosterone, DHT and estradiol for men that were administered Placebo then Testosterone 
(Group B, n=22, Mean±SD). 
 
 Baseline (Week 0) Placebo (Week 24) Wash Out Testosterone (Week 52) 
MMSE1 27.05±1.64 27.82±1.3 27.77±1.5 28.14±1.8* 
RAVLT2      
Immediate Recall3 42.4±9 44.1±8.2 47.4±8.6 46.7±10.2 
Delayed Recall 8.5±3 8.1±3.2 9.8±2.8 9.7±3.5 
GDS4 6.4±5.6 4.9±3.9 4.9±4.5 4.5±4* 
Testosterone (nmol/L) 17.9±6.3 16.6±4.6 16.8±5.9 24.5±13.8*# 
DHT (nmol/L) 2.8±0.8 1.7±0.9 1.7±1.6 8.4±5.7*# 
Estradiol (pmol/L) 85.8±26.4 88.4±29.6 84.8±29.3 91.3±40.1 
LH (U/L) 4.7±2.6 5.6±3.4 4.6±1.9 3.1±2.6* # 
1Mini Mental State Examination; 2Rey Auditory Verbal Learning Test; 3RAVLT Learning Trial 1-5 total score; 4Geriatric Depression Scale. *p<0.05, values significantly different 
from baseline; #p<0.05, values significantly different from placebo. 
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were in the lower one-third of the normal range for men. We 
believe our mode of application of testosterone on the 
scrotum explains the above finding with testosterone being 
converted to DHT and thus not being susceptible to 
aromatization which is usually observed in older men [24]. 
 Our study shows that, albeit modestly, testosterone can 
increase baseline global cognition following 24 weeks but 
taken together with the above mentioned studies, it also 
highlights the need for further validation studies. These may 
involve a longer follow-up periods, reversing treatment to 
placebo after the crossover completion or an open label study 
following completion. As highlighted in a study of 500 
elderly men that lower testosterone levels at baseline was 
associated with a higher risk of cognitive decline at a 2 year 
follow up [25]. Thus follow-up studies with larger 
participants and longer treatment durations are required to 
determine the efficacy of testosterone in preventing or 
slowing down the progression of cognitive decline. 
 Depression symptoms can contribute to future cognitive 
decline in older adults [26, 27]. Studies of testosterone 
treatment in relation to depression levels have produced 
conflicting results. It is likely that the relationship is complex 
in nature and involves interaction between genetic, 
environmental and lifestyle factors. Some studies have 
shown no association between endogenous testosterone 
levels and depressive symptoms [28] and may not be 
beneficial for patients who have reached a clinical 
depression state or are highly depressed [29]. However, a 
significant improvement in depression following testosterone 
treatment has been previously reported, with one study 
observing the strongest effect in men with the lowest 
baseline total testosterone [30]. It was shown that men with 
sub-threshold levels of depression treated with testosterone 
had greater reductions in symptoms of depression than 
placebo treated men [31]. Furthermore, a recent study by 
Cherrier et al. (2015) reported that men with MCI and low 
testosterone levels had decreased depression symptoms 
following 6 month transdermal testosterone gel treatment 
[20]. In the present study, compared to baseline, depression 
levels decreased following testosterone treatment in both 
treatment arms. In TP treatment (Group A), GDS scores 
were reduced following administering testosterone, in the 
wash-out period and following administering placebo. This 
could be partially explained by the lasting benefits of 
testosterone (similar to the effects on global cognition). 
However, further reduction was observed when placebo at 52 
weeks was compared to testosterone at 24 weeks. In 
addition, in the PT treatment (Group B), although not 
significant, there was a trend towards a reduction when 
placebo was administered with a further reduction following 
testosterone treatment. Overall, these results may suggest a 
placebo effect on reducing GDS scores. As discussed above 
the low dose of Vitamin E within the creams is not likely to 
confer benefits over the treatment period. Other factors may 
contribute such as being active in the trial and engaging with 
researchers on a regular basis. 
 It is also difficult to determine whether there is a placebo 
effect in interpreting this result when the course of 
development of AD is unknown in this cohort [32]. The 
physician-patient relationship which resulted in the  
 
expectations and motivations of the patient thus probably 
also has modifying changes on the placebo response [33], 
and where there is no untreated (control) group to define the 
true placebo effect [33, 34]. 
CONCLUSION 
 Some limitations of the present study should be 
acknowledged. Although larger than some of the previous 
studies, this study was relatively underpowered with small 
sample sizes (n=44) to conclusively determine testosterone 
treatment on cognition. It is also possible that our memory 
measure, the RAVLT, was not able to detect small or subtle 
changes in cognitively intact participants even though we 
used parallel forms to avoid the practice effect and the 
RAVLT has proven to appropriately evaluate episodic verbal 
memory [11]. Despite these limitations, this is the first 
double blind randomized crossover placebo-controlled study 
that evaluated the effect of short term testosterone treatment 
on cognitive functioning in older men with low to low-
normal testosterone levels and who have a subjective 
memory complaint. When combined with genetic risk 
factors, brain amyloid imaging and other AD related 
biomarkers, subjective memory complainers are at higher 
risk of clinically defined cognitive decline than non-memory 
complainers. We have also previously shown that in addition 
to APOEε4, changes in hormone levels (LH) is strongly 
correlated with greater brain amyloid load in subjective 
memory complainers [2], providing further support that this 
is an appropriate cohort to include in such a trial. Data from 
our current study indicated that testosterone supplementation 
lowered LH, investigating the impact on the association 
between LH and brain amyloid load in subjective memory 
complainers would be further warranted. Our findings of a 
modest improvement from baseline in global cognition are 
promising but require comprehensive larger longer term 
studies to investigate the efficacy of testosterone treatment 
on cognitive and clinical measures with the inclusion of 
blood and brain imaging markers. 
TRIAL REGISTRATION 
 The Australian New Zealand Clinical Trials Registry 
(ANZCTR). Trial ID ACTRN12614000277640. 
LIST OF ABBREVIATIONS 
AD = Alzheimer’s Disease 
DHT = Dihydrotestosterone 
GDS = Geriatric Depression Scale 
LH = Luteinizing Hormone 
MCI = Mild Cognitive Impairment 
MMSE = Mini Mental State Examination 
P = Placebo 
PSA = Prostate Specific Antigen 
RAVLT = Rey Auditory Verbal Learning Test 
T = Testosterone 
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